Influence of nucleotide excision repair on mitoxantrone cytotoxicity

Au, 1981, Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin, Cancer Res., 41, 376 Faulds, 1991, Mitoxantrone a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer, Drugs, 41, 400, 10.2165/00003495-199141030-00007 Chugun, 2008, Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations, J. Vet. Med. Sci., 70, 255, 10.1292/jvms.70.255 Nitiss, 2009, Targeting D.N.A. topoisomerase II in cancer chemotherapy, Nat. Rev. Cancer, 9, 338, 10.1038/nrc2607 Parker, 2004, A molecular understanding of mitoxantrone-DNA adducts formation, J. Biol. Chem., 279, 18814, 10.1074/jbc.M400931200 Skladanowski, 2000, Mitoxantrone and amemantrone induce interstrand cross-links in DNA of tumour cells, Br. J. Cancer, 82, 1300, 10.1054/bjoc.1999.1095 Huang, 2006, Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine, Cancer Biol. Ther., 5, 959, 10.4161/cbt.5.8.2878 Curtin, 2012, DNA repair dysregulation from cancer driver to therapeutic target, Nat. Rev. Cancer, 12, 801, 10.1038/nrc3399 Schellenberg, 2012, Mechanism of 5′ topoisomerase II DNA adduct repair by mammalian tyrosyl DNA phosphodiesterase 2, Nat. Struct. Mol. Biol., 19, 1363, 10.1038/nsmb.2418 Pommier, 2013, Drugging Topoisomerases: lessons and challenges, ACS Chem. Biol., 18, 82, 10.1021/cb300648v Saffi, 2010, Effect of the anti-neoplastic drug doxorubicin on XP-mutated DNA repair-deficient human cells, DNA Repair, 9, 40, 10.1016/j.dnarep.2009.10.003 Moraes, 2012, Both XPA and DNA polymerase Eta are necessary for the repair of doxorubicin-induced DNA lesions, Cancer Lett., 314, 108, 10.1016/j.canlet.2011.09.019 Carvalho, 2010, DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells, Cancer Chemother. Pharmacol., 65, 989, 10.1007/s00280-010-1244-x Costa, 2003, The eukaryotic nucleotide excision repair pathway, Biochimie, 85, 1083, 10.1016/j.biochi.2003.10.017 Shuck, 2008, Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology, Cell Res., 18, 64, 10.1038/cr.2008.2 Lehmann, 2011, Xeroderma pigmentosum, Orphanet J. Rare Dis., 6, 70, 10.1186/1750-1172-6-70 Sarasin, 2007, New insights for understanding the transcription-coupled repair pathway, DNA Repair, 6, 265, 10.1016/j.dnarep.2006.12.001 Hoejimakers, 2009, D.N.A damage aging, and cancer, N. Engl. J. Med., 361, 1474 Singh, 1988, A simple technique for quantification of low levels of DNA damage in individual cells, Exp. Cell Res., 175, 184, 10.1016/0014-4827(88)90265-0 Collins, 2004, The comet assay for DNA damage and repair: principles, applications, and limitations, Mol. Biotechnol., 26, 249, 10.1385/MB:26:3:249 Wilmore, 1998, Etoposide targets topoisomerase IIa and IIb in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique, Mol. Pharmacol., 53, 78, 10.1124/mol.54.1.78 Potter, 2005, The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs, Mutat. Res., 572, 27, 10.1016/j.mrfmmm.2004.11.018 D’Errico, 2013, The role of CSA and CSB protein in the oxidative stress response, Mech. Ageing Dev., 134, 261, 10.1016/j.mad.2013.03.006 Andrade, 2012, Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome, Hum. Mol. Genet., 21, 3825, 10.1093/hmg/dds211 Spencer, 2008, DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair, Mutat. Res., 638, 110, 10.1016/j.mrfmmm.2007.09.005 Smart, 2008, Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone, Mutat. Res., 641, 43, 10.1016/j.mrfmmm.2008.03.005 Huang, 2004, Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-Linking agent cisplatin, Cytometry A, 58, 99, 10.1002/cyto.a.20018 Ward, 2001, Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress, J. Biol. Chem., 276, 47759, 10.1074/jbc.C100569200 Marti, 2006, H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks, Proc. Natl. Acad. Sci. U. S. A., 103, 9891, 10.1073/pnas.0603779103 Hanasoge, 2007, H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase, Carcinogenesis, 28, 2298, 10.1093/carcin/bgm157 Koceva-Chyla, 2005, Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation, Apoptosis, 10, 1497, 10.1007/s10495-005-1540-9 Zhao, 2008, Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase, Cytometry A., 73, 480, 10.1002/cyto.a.20574 Seifrtova, 2013, Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts, J. Physiol. Pharmacol., 64, 255 Kule, 1994, Doxorubicin, daunarubicin, and mitoxantrone cytotoxicity in yeast, Mol. Pharmacol., 46, 1234 Barasch, 1999, Novel anthraquinone derivatives with redox-active functional groups capable of producing free radicals by metabolism: are free radicals essential for cytotoxicity, Eur. J. Med. Chem., 34, 597, 10.1016/S0223-5234(00)80029-X Blasiak, 2002, A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone, Acta Biochim. Pol., 49, 145, 10.18388/abp.2002_3831 Errington, 2004, Differences in the longevity of topo II alpha and topo II beta drug-stabilized cleavable complexes and the relationship to drug sensitivity, Cancer Chemother. Pharmacol., 53, 156 Horibata, 2011, Mutant Cockayne syndrome group B protein inhibits repair of DNA topoisomerase I-DNA covalent complexes, Genes Cells, 16, 101, 10.1111/j.1365-2443.2010.01467.x Sakai, 2012, PARP and CSB modulate the processing of transcription-mediated DNA strand breaks, Genes Genet. Syst., 87, 265, 10.1266/ggs.87.265 Mao, 2001, 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes, J. Biol. Chem., 276, 40652, 10.1074/jbc.M104009200 Gao, 2014, Proteolitic degradation of topoisomerase II (Top2) enables the processing of Top2-DNA and Top2-RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2), J. Biol. Chem., 289, 17960, 10.1074/jbc.M114.565374 Gómez-Herreros, 2013, TDP2–dependent non-homologous end-joining protects against topoisomerase II–induced DNA. Breaks and genome instability in cells and in vivo, PLoS Genet., 9, 10.1371/journal.pgen.1003226 Bregmann, 1996, UV-induced ubiquitination of RNA-polymerase II: a novel modification deficient in Cockayne syndrome cells, Proc. Natl. Acad. Sci., 93, 11586, 10.1073/pnas.93.21.11586 Latini, 2011, CSA and CSB proteins interact with p53 and regulate its Mdm2-dependent ubiquitination, Cell Cycle, 10, 3719, 10.4161/cc.10.21.17905